Warfarin
DrugWarfarin
NCT Number: NCT00235248
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology. The objective is to compare the efficacy and tolerance (net benefit) of two antithrombotic strategies in patients with atherothrombosis of the aortic arch and a recent (less than 6 months) cerebral or peripheral embolic event.
Hypothesis:
The association of clopidogrel 75 mg/d plus aspirin 75 mg/d is 25% more effective than an oral anticoagulant (target International Normalized Ratio [INR] 2 to 3) in preventing brain infarction, brain hemorrhage, myocardial infarction, peripheral embolism, and vascular death.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
National Stroke Research Institute-Austin Health, Heidelberg Heights, Australia
Patients with Transient Ischemic attack or brain infarction of unknown cause (no ipsilateral internal carotid artery origin stenosis greater than 70%, no ipsilateral severe intracranial stenosis of an artery supplying the infarcted area, no definite cardiac source of embolism) in the preceding 6 months and atherosclerotic plaques.
≥ 4 mm in the aortic arch, or patients with a peripheral event (e.g. renal infarct) in the preceding 6 months and plaque ≥ 4 mm in the thoracic aorta above the origin of the embolized artery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria:
Exclusion criteria
Warfarin
Clopidogrel-aspirin
Time frame: every 4 months
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
Time frame: during the trial
Recurrent brain infarction
Time frame: during the studing
brain infarction and transient ischemic attack (TIA)
Time frame: during the trial
new vascular events and revascularization procedure
Time frame: during the trial
vascular death
Time frame: during the trial
death from all causes
Time frame: during the trial
combination of primary end-point and TIA
Time frame: during the trial
revascularization procedures
Time frame: during the trial
urgent rehospitalization for ischemic
Assistance Publique - Hôpitaux de Paris
Other
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery
Acronym: ARCH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04043559
Brain Diseases, Brain Infarction
Nîmes, France
View Trial DetailsNCT04941482
Behavior, Brain Diseases
Hanoi, Vietnam
View Trial DetailsNCT05086874
Brain Diseases, Brain Infarction
Jinan, Shandong Provincial, China
View Trial DetailsNCT02684825
Arrhythmias, Cardiac, Atrial Fibrillation
Rome, Italy
View Trial Details